The monoclonal antibody T2-2 was originally raised against the colorectal carcinoma cell line LS174T and was found to bind to several other human carcinomas, including hepatoma and ovarian cancer. The goal of this study was to investigate the antitumor activity of mAb T2-2 in human tumor models and further characterize the antigen. mAb T2-2 inhibited the growth of human hepatocellular cell line SMMC 7721 in vivo and in vitro. Western blot analysis revealed that this mAb recognizes an unique Mr 45,000 band from tissue extracts of human hepatocellular carcinoma (HCC), which localizes to the cell periphery. In vitro cell assays indicate that T2-2 decreases cell adhesion to laminin, implying the functional role of T2-2 antigen in cell-matrix interaction and cell migration.